12:00 AM
 | 
Jan 29, 2007
 |  BioCentury  |  Product Development

Expanding Velcade sales

Expanding Velcade sales

Product DevelopmentExpanding Velcade salesTo grow sales of its key drug, Velcade bortezomib, Millennium Pharmaceuticals Inc. is taking a multi-pronged approach that includes earlier use of the proteasome inhibitor in its approved indication of multiple myeloma, getting doctors to prescribe more cycles of the drug in its approved indications, and adding new indications in larger cancer markets. Velcade already has a foothold in the first-line setting for MM, as the company has estimated that off-label use suggests 10% penetration. The company...

Read the full 400 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >